Results 171 to 180 of about 75,980 (291)

A Prospective, Multicenter, Open Label Study Investigating the Implementation of a Standardized Algorithm for Coronary CaLcificatiOn With PlaquE Modification Using UltraSound Guidance to Improve Procedural and Clinical Outcomes (CYCLOPES): Design and Rationale of the CYCLOPES Trial

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Introduction Moderate‐to‐severe calcification is present in ~20%–30% of patients undergoing coronary angiography. Coronary lesion modification is often necessary to facilitate optimal stent delivery and expansion, with several dedicated devices now approved for calcium modification before stent implantation. The CYCLOPES study aims to evaluate
Daniel O'Callaghan   +14 more
wiley   +1 more source

Clinical Impact of Angiographic Complications Occurring During Percutaneous Coronary Interventions

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The clinical impact of different types of angiographic complications during elective PCIs remains largely unexplored. Aims To explore the incidence, management, and outcomes of angiographic complications by type and severity during non‐urgent, non‐CTO PCIs. Methods Clinical and procedural characteristics were prospectively collected
Emiliano Bianchini   +16 more
wiley   +1 more source

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko   +15 more
wiley   +1 more source

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park   +22 more
wiley   +1 more source

Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5*6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5*6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%)
Amar D. Levens   +10 more
wiley   +1 more source

Discrete-time neural Markov models. [PDF]

open access: yesBMC Med Res Methodol
Sundell J, Wahlquist Y, Soltesz K.
europepmc   +1 more source

Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Abemaciclib is an oral anticancer drug indicated for treatment of HR+ HER2‐ breast cancer. Dose modifications due to side effects are frequent, thus drug exposures change over time as a result of altering the dose or temporarily withholding abemaciclib treatment.
Emmanuel Chigutsa   +2 more
wiley   +1 more source

A practical overview and statistical analysis of interval-censored data in cancer. [PDF]

open access: yesCancer Commun (Lond)
Dey T   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy